Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†.
Apoptosis
/ drug effects
Cell Cycle Proteins
/ genetics
Cell Proliferation
/ drug effects
Cells, Cultured
Decidua
/ cytology
Embryo Implantation
/ drug effects
Female
Growth Hormone-Releasing Hormone
/ antagonists & inhibitors
Humans
MAP Kinase Signaling System
/ drug effects
Pregnancy
Sermorelin
/ analogs & derivatives
Stromal Cells
/ drug effects
Up-Regulation
/ drug effects
ERK1/2
GADD45α
GHRH antagonist
JNK
apoptosis
Journal
Biology of reproduction
ISSN: 1529-7268
Titre abrégé: Biol Reprod
Pays: United States
ID NLM: 0207224
Informations de publication
Date de publication:
13 01 2022
13 01 2022
Historique:
received:
19
07
2021
revised:
22
10
2021
accepted:
11
11
2021
pubmed:
19
11
2021
medline:
19
2
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Endometrial stromal cells remodeling is critical during human pregnancy. Growth hormone-releasing hormone and its functional receptor have been shown to be expressed in gynecological cancer cells and eutopic endometrial stromal cells. Recent studies have demonstrated the potential clinical uses of antagonists of growth hormone-releasing hormone as effective antitumor agents because of its directly antagonistic effect on the locally produced growth hormone-releasing hormone in gynecological tumors. However, the impact of growth hormone-releasing hormone antagonists on normal endometrial stromal cell growth remained to be elucidated. The aim of this study was to investigate the effect of a growth hormone-releasing hormone antagonist (JMR-132) on cell proliferation and apoptosis of human decidual stromal cells and the underlying molecular mechanisms. Our results showed that growth hormone-releasing hormone and the splice variant 1 of growth hormone-releasing hormone receptor are expressed in human decidual stromal cells isolated from the decidual tissues of early pregnant women receiving surgical abortion. In addition, treatment of stroma cells with JMR-132 induced cell apoptosis with increasing cleaved caspase-3 and caspase-9 activities and decrease cell viability in a time- and dose-dependent manner. Using a dual inhibition approach (pharmacological inhibitors and siRNA-mediated knockdown), we showed that JMR-132-induced activation of apoptotic signals are mediated by the activation of ERK1/2 and JNK signaling pathways and the subsequent upregulation of GADD45alpha. Taken together, JMR-132 suppresses cell survival of decidual stromal cells by inducing apoptosis through the activation of ERK1/2- and JNK-mediated upregulation of GADD45alpha in human endometrial stromal cells. Our findings provide new insights into the potential impact of growth hormone-releasing hormone antagonist on the decidual programming in humans.
Identifiants
pubmed: 34792103
pii: 6430848
doi: 10.1093/biolre/ioab214
doi:
Substances chimiques
Cell Cycle Proteins
0
GADD45A protein, human
0
GHRH protein, human
0
GHRH(1-29)NH2, PhAcTyr(1)-Arg(2)-P(H)e(4-CL)(6)-Ala(8)-Tyr(Me)(10)-His(11)-Abu(15)-His(20)-Nle(27)-Arg(28)-HLCr(29)-
0
Sermorelin
86168-78-7
Growth Hormone-Releasing Hormone
9034-39-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-154Subventions
Organisme : BLRD VA
ID : I01 BX005051
Pays : United States
Organisme : CIHR
Pays : Canada
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.